Advances in prostate cancer immunotherapy

Surgical Oncology

Volumn 11, Issue 1-2, 2002, Pages 35-45

  Havranek, E G ^a   Whelan, M A ^a   Greenhalgh, R ^a   Dalgleish, A G ^b   Pandha, H ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Immunotherapy; Prostate cancer; Review; Whole cell vaccines

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; BETA 2 MICROGLOBULIN; BETA INTERFERON; CANCER VACCINE; CYCLOPHOSPHAMIDE; DNA VACCINE; FAS LIGAND; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2IR BAD M170 IN 111; MONOCLONAL ANTIBODY 2IR BAD M180 Y 90; MYCOBACTERIUM VACCINE; ONCOVAX P; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE PAIN; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFUSION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DYSURIA; EFFECTOR CELL; FEVER; HUMAN; IMMUNE STATUS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TH1 CELL; TH2 CELL; TUMOR IMMUNOLOGY; VACCINATION; VISUAL IMPAIRMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CYTOKINES; DENDRITIC CELLS; GANCICLOVIR; GENE THERAPY; HUMANS; IMMUNOTHERAPY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RATS; VACCINES, DNA;

EID: 0036273176     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-7404(02)00012-9     Document Type: Article

References (115)

1. Prostate cancer immunotherapy at the dawn of the new millennium
2. Immunological surveillance in neoplasia
3. Immunological aspects of malignant disease
4. Tumor vaccine design: Concepts, mechanisms, and efficacy testing
5. Graft tolerance: A duel of two signals
6. Immunotherapy in lung cancer
7. Tumor antigens recognized by T cells
8. Pulmonary perspective: Immunology in diagnosis and treatment of lung cancer
9. Physiologic functions of activating natural killer (NK) complex-encoded receptors on NK cells
10. The role of immunotherapy for urological tumours
11. Cytokines in innate and adaptive immunity
12. The role of dendritic cells in the innate immune system
13. Recombinant antibodies with the antigen-specific, MHC restricted specificity of T cells: Novel reagents for basic and clinical investigations and immunotherapy
14. The Th1/Th2 paradigm
15. Cytokine-modulated regulation of helper T cell populations
16. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer
17. Cancer vaccines
18. Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor
19. Occult carcinoma of the prostate: An oversight of immune surveillance - A working hypothesis
20. Granulomatous prostatitis. A mimic of carcinoma of the prostate
21. The lymphatic drainage of the rat prostate and its status as an immunologically priviledged site
22. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma
23. Immune evaluation with skin testing. A study of testicular, prostatic, and bladder neoplasms
24. Impaired cytokine production in whole blood cell cultures of patients with urological carcinomas
25. Immunotherapy of advanced prostate cancer: A phase i/ii trial using mycobacterium vaccae (srl172)
26. Loss of HLA class I expression in prostate cancer: Implications for immunotherapy
27. Molecular characterization of defective antigen processing in human prostate cancer
28. Immunobiology and immunotherapy of melanoma
29. Protease inhibitors interfere with the transforming growth factor-beta- dependent but not the transforming growth factor-beta-independent pathway of tumor cell-mediated immunosuppression
30. Preventing abnormalities in signal transduction of T cells in cancer: The promise of cytokine gene therapy
31. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
32. Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer
33. Nonspecific immunotherapy in GU cancer
34. Immunologic approaches to the treatment of prostate cancer
35. Gene therapy for prostate cancer
36. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
37. Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens
38. TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49
39. A novel prostate carcinoma-associated glycoprotein complex (PAC) recognized by monoclonal antibody TURP-27
40. Expression of oncogenic antigen 519 (OA-519) in prostate cancer is a potential prognostic indicator
41. Active specific immunotherapy: Pem as a potential target molecule
42. Genetic alterations in prostate cancer
43. P53 oncogene mutations in human prostate cancer specimens
44. P53 in prostate cancer: Frequent expressed transition mutations
45. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer
46. Expression of the prostate-specific membrane antigen
47. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers
48. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
49. Animal cell cycle
50. Monoclonal antibody treatment of solid tumors: A coming of age
51. Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer
52. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3)
53. Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu
54. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
55. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody
56. A novel method for the detection of necrotic lesions in human cancers
57. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: Effect of dose and EDTA coadministration on pharmacokinetics and toxicity
58. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177- CC49
59. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells
60. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response
61. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+T lymphocytes, and NK cells
62. T cells bearing/IFN-gamma receptor in human transitional cell carcinoma of the bladder
63. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
64. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4
65. Regression of bladder tumors in mice treated with interleukin 2 gene- modified tumor cells
66. Intravenous, intralesional and endolymphatic administration of lymphokines in human cancer
67. Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant
68. Paracrine cytokine adjuvants in cancer immunotherapy
69. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector
70. Induction of antibodies to prostate specific antigen by oncovax-p, a liposome-based vaccine therapy of prostate cancer
71. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial
72. In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer-changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile
73. Prostate specific antigenic peptides induce T cell proliferation in-vitro: A model for the development of prostate specific tumor vaccines
74. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen
75. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity
76. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide
77. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer
78. Progress in active specific immunotherapy of prostate cancer
79. Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques
80. HER-2/neu oncogenic protein: Issues in vaccine development
81. Active specific T-cell-based immunotherapy for cancer: Nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. principles and future prospects
82. Direct gene transfer into mouse muscle in vivo
83. Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy
84. The Immunology of DNA vaccines
85. Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen
86. Do DNA vaccines induce autoimmune disease?
87. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
88. Allogenic whole cell vaccine: A phase I/II study in men with hormone refractory cancer
89. Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo
90. Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumor vaccines
91. Demonstration of a rational strategy for human prostate cancer gene therapy
92. Allogeneic murine melanoma cell vaccine: A model for the development of human allogeneic cancer vaccine
93. Comparison of IL-2- and IL-4-transfected B16-F10 cells with a novel oil- microemulsion adjuvant for B16-F10 whole cell tumour vaccine
94. Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer
95. Immunotherapy I: Cytokine gene transfer strategies
96. Antitumor vaccination: Where we stand
97. Current treatment modalities in advanced colorectal carcinoma
98. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
99. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine
100. Comparison of gene therapy with the herpes simplex virus thymidine kinase gene and the bacterial cytosine deaminase gene for the treatment of hepatocellular carcinoma
101. Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques
102. In vivo analysis of the 'bystander effect': A cytokine cascade
103. In situ gene therapy for adenocarcinoma of the prostate: A phase i clinical trial
104. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer
105. Cytopathic effect of in situ gene therapy in prostate cancer
106. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution
107. Distinct populations of dendritic cells are present in the subepithelial dome and T cell regions of the murine Peyer's patch
108. Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen
109. The immunologic properties of epidermal Langerhans cells as a part of the dendritic cell system
110. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma
111. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
112. In vivo maturation and migration of dendritic cells
113. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine
114. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells